Ranee Mehra
Impact in
- Otorhinolaryngology top 0.1%
- Head and Neck Cancer Studies
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
Papers in
-
- Head and Neck Cancer Studies 61
- Oncology 69
- Lung Cancer Research Studies 19
- Cancer Immunotherapy and Biomarkers 19
- Cancer Diagnosis and Treatment 7
- HER2/EGFR in Cancer Research 7
- CAR-T cell therapy research 6
- Co-authors
- Barbara Ann Burtness (41 shared papers)Laura Q.M. Chow (8 shared papers)Jonathan D. Cheng (4 shared papers)Joseph P. Eder (3 shared papers)Jared Weiss (3 shared papers)Tanguy Y. Seiwert (4 shared papers)John Andrew Ridge (30 shared papers)Jared K. Lunceford (2 shared papers)
- Journals
- International Journal of Radiation Oncology*Biology*Physics (16 papers)Annals of Oncology (16 papers)Head & Neck (13 papers)Oral Oncology (8 papers)Clinical Cancer Research (6 papers)
- Partner nations
- United StatesItalySouth Korea
In The Last Decade
Ranee Mehra
159 papers receiving 10.8k citations
Ranee Mehra's Hit Papers
Peers
Comparison fields: 5 of 123
- Otorhinolaryngology 2.5k
- Oncology 5.3k
- Pulmonary and Respiratory Medicine 3.4k
- Cancer Research 1.1k
- Immunology 1.2k
Countries citing papers authored by Ranee Mehra
This map shows the geographic impact of Ranee Mehra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ranee Mehra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ranee Mehra more than expected).
Fields of papers citing papers by Ranee Mehra
This network shows the impact of papers produced by Ranee Mehra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ranee Mehra. The network helps show where Ranee Mehra may publish in the future.
Co-authors
The 25 scholars most cited alongside Ranee Mehra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 168 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial Hit paper breakdown → | 2016 | 1433 |
| 2 | Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Hit paper breakdown → | 2018 | 1366 |
| 3 | Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer Hit paper breakdown → | 2014 | 1236 |
| 4 | Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort Hit paper breakdown → | 2016 | 715 |
| 5 | Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer Hit paper breakdown → | 2011 | 489 |
| 6 | Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer Hit paper breakdown → | 2014 | 420 |
| 7 | Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial Hit paper breakdown → | 2016 | 402 |
| 8 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 Hit paper breakdown → | 2018 | 368 |
| 9 | Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States Hit paper breakdown → | 2015 | 335 |
| 10 | 2018 | 271 | |
| 11 | 2019 | 199 | |
| 12 | 2015 | 158 | |
| 13 | 2017 | 144 | |
| 14 | 2016 | 130 | |
| 15 | 2014 | 129 | |
| 16 | 2012 | 127 | |
| 17 | 2017 | 112 | |
| 18 | 2017 | 107 | |
| 19 | 2018 | 107 | |
| 20 | 2015 | 92 |
About Ranee Mehra
Ranee Mehra is a scholar working on Otorhinolaryngology, Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 168 papers that have together received 11.0k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (61 papers), Lung Cancer Treatments and Mutations (52 papers), Lung Cancer Research Studies (19 papers), Cancer Immunotherapy and Biomarkers (19 papers), Cancer therapeutics and mechanisms (10 papers), Cancer Diagnosis and Treatment (7 papers), HER2/EGFR in Cancer Research (7 papers) and CAR-T cell therapy research (6 papers). The work is most often cited by research in Otorhinolaryngology (2.5k citations), Oncology (5.3k citations), Pulmonary and Respiratory Medicine (3.4k citations), Cancer Research (1.1k citations) and Immunology (1.2k citations). Ranee Mehra has collaborated with scholars based in United States, Italy and South Korea. Frequent co-authors include Barbara Ann Burtness, Laura Q.M. Chow, Jonathan D. Cheng, Joseph P. Eder, Jared Weiss, Tanguy Y. Seiwert, John Andrew Ridge, Jared K. Lunceford, Thomas James Galloway and Karl Heath. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Annals of Oncology, Head & Neck, Oral Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.